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Objectives. We attempted to assess insulin sensitivity in pa-
tients with chronic heart failure (CHF) and its relation to disease
severity.
Background. Peripheral muscular changes influence the pro-
gression of heart failure. This effect may be due to chronic
disturbances of insulin and glucose metabolism that affect the
energy status of skeletal and myocardial muscle.
Methods. We investigated insulin sensitivity in 79 men—38
patients with CHF, 21 patients with angiographic evidence of
coronary artery disease without CHF and 20 healthy control
subjects—and assessed its relation to disease severity, etiology
and hormonal status (all subjects had a similar age and body
mass index). Insulin sensitivity was estimated by minimal model-
ing analysis of the glucose and insulin and profiles during a
0.5-g/kg body weight intravenous glucose tolerance test.
Results. Compared with control subjects, patients with CHF
had similar mean fasting glucose but increased insulin levels (67
vs. 29 pmol/liter, p < 0.002) and a 58% reduced mean insulin
sensitivity (2.01 vs. 4.84 min21/pmol/ml 3 105, p < 0.0001). Peak
oxygen consumption (VO2) (r 5 0.63), fasting triglycerides (r 5
20.62) and age (r 5 20.46, all p < 0.001) predicted insulin
sensitivity independently. Rest norepinephrine and epinephrine
levels, left ventricular ejection fraction and heart failure etiology
were not related to insulin sensitivity. Patients with coronary
artery disease but no CHF had an intermediate mean insulin
sensitivity (3.30 min21/pmol/ml 3 105 [232%, p 5 0.042 vs.
control subjects; 1113%, p 5 0.0023 vs. patients with CHF due to
ischemic heart disease]). In multivariate analyses of all 79
subjects, age (p 5 0.0006), triglycerides (p 5 0.0023), fasting
insulin (p 5 0.0037) and the presence of CHF (p 5 0.018) were
independent predictors of impaired insulin sensitivity (adjusted
joint R2 5 0.53, p < 0.0001).
Conclusions. CHF is associated with marked insulin resistance,
characterized by both fasting and stimulated hyperinsulinemia.
Advanced heart failure (in terms of reduced peak VO2) is related
to increased insulin resistance, but this is not directly mediated
through ventricular dysfunction or increased catecholamine
levels.
(J Am Coll Cardiol 1997;30:527–32)
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Insulin resistance is implicated in several potentially adverse
metabolic changes, including disturbances in insulin and glu-
cose metabolism, which can affect energy supply and blood
flow to both myocardial and skeletal muscle (1,2). A previous
pilot study in 10 patients with severe chronic heart failure
(CHF) due to ischemic heart disease (3) suggested that these
patients were insulin resistant. CHF is a heterogeneous syn-
drome with an overall adverse prognosis. Insulin resistance in
patients with CHF could contribute to both the progressive
deterioration of myocardial function and the peripheral clini-
cal features that occur once heart failure has become estab-
lished.
The purpose of this study was to establish whether insulin
resistance is common in CHF. We therefore examined the
association between the degree of insulin resistance and both
severity and etiology of CHF in 38 patients with a wide range
of clinical severity of CHF. Patients with CHF due to coronary
artery disease are more likely to have abnormalities in glucose
metabolism than are patients with CHF due to idiopathic
dilated cardiomyopathy. Therefore, we also studied a control
group of patients with coronary artery disease without heart
failure. We aimed to detect whether the presence of heart
failure is an independent risk factor for impaired insulin
sensitivity.
Methods
Patients with heart failure and control subjects. The pri-
mary study group consisted of 38 white male patients with CHF
and 20 healthy male control subjects of similar age and weight.
Patients were included in the study if they had stable CHF, due
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to left ventricular systolic dysfunction, of $6 months’ duration.
Known diabetic patients were excluded from study. On the day
of study no patient showed clinical signs of fluid overload,
peripheral or pulmonary edema or significant elevation of
jugular venous pressure. The diagnosis of ischemic heart
disease was based on documentation of previous myocardial
infarction, coronary artery bypass surgery or pathologic find-
ings on coronary angiography. Idiopathic dilated cardiomyop-
athy was diagnosed in the absence of a specific etiology for left
ventricular dysfunction and on the basis of normal coronary
arteries. All patients were stable with treatment and had had
no change in their treatment regimen for $6 weeks before the
study. The majority of patients were taking furosemide (n 5
33) and an angiotensin-converting enzyme (ACE) inhibitor
(n 5 31). Other pharmacologic drugs in use included aspirin
(n 5 16), nitrates (n 5 13), warfarin (n 5 13), amiodarone
(n 5 11), digoxin (n 5 11) and amiloride (n 5 9). The mean
furosemide equivalent dose in patients was 128 6 21 mg. None
of these agents is known to have a deleterious effect on insulin
or carbohydrate metabolism, although ACE inhibitors might
improve insulin sensitivity. No patient was receiving antidia-
betic treatment before study entry. The patients had not taken
medication for $12 h before the study.
The 20 control subjects were clinically healthy, asymptom-
atic volunteers who were seen as part of a routine health
screening program. They were taking no medication. All
patients and volunteers gave written informed consent, and
the protocol was approved by the Ethics Committee of the
Royal Brompton Hospital, London as well as by the Ethics
Committee of the Wynn Institute of Metabolic Medicine,
London.
Patients with coronary artery disease. We also present the
results of a study in a contemporary group of male patients
with angiographically documented coronary artery disease
(.50% stenosis of one or more epicardial coronary arteries).
Between 1990 and 1992, our group (4) studied 39 such
patients. For the present analysis we identified 21 of those
patients who were best matched in age and body mass index
with the 21 patients with CHF due to coronary artery disease.
Ten of these patients had a history of myocardial infarction,
but not within 6 months of participating in this study. None of
these patients had taken drugs known to affect lipid or
carbohydrate metabolism in the previous 6 months, and they
presented no symptoms of heart failure.
Insulin sensitivity. After an overnight fast, all subjects
underwent an intravenous glucose tolerance test with the
injection of a single bolus of glucose (0.5 g/kg body weight)
over 3 min given as 20% dextrose. Venous blood samples were
drawn to measure plasma glucose, insulin and C-peptide
concentrations (3) at baseline and at 3, 5, 7, 10, 15, 20, 30, 45,
60, 75, 90, 120, 150 and 180 min. The level of C-peptide
characterizes insulin secretion. Incremental glucose, insulin
and C-peptide areas (i.e., the area between measured profile
and rest level) were calculated by the trapezium rule. Insulin
sensitivity was measured by using the minimal model of
Bergman et al. (5). The model provides two summary vari-
ables: 1) insulin sensitivity (S inversely proportional to insulin
resistance), and 2) an index of glucose-dependent glucose
elimination (3). The modeling procedure was successful in all
but one study subject. We (6) have previously demonstrated a
highly significant correlation between insulin sensitivity esti-
mates from the minimal model and the results of the euglyce-
mic clamp reference technique (r 5 0.92) in control subjects
and patients with CHF. The intravenous glucose tolerance test
was preferable in the present study because it is less invasive
and requires less fluid loading.
Evaluation of clinical status. On the day of study all
subjects were physically examined. All patients with CHF and
the healthy volunteers performed a maximal treadmill exercise
test (modified Bruce protocol, Amis 2000, Odense, Denmark
[7]). The maximal oxygen consumption (peak VO2 in ml/kg per
min) and the ventilation/carbon dioxide slope were measured
(this was not possible in one control subject). To assess the
severity of ventricular dysfunction in patients with CHF, we
measured the left ventricular ejection fraction by using radio-
nuclide ventriculography. From the venous blood samples
taken at baseline before the glucose tolerance test in healthy
control subjects and patients with CHF, hormones were deter-
mined that indicate the severity of heart failure: aldosterone
(DPC; sensitivity 16 pg/ml), plasma renin activity (Biodata
SPA, Italy; sensitivity 0.039 ng/ml per h), epinephrine and
norepinephrine. The catecholamines are also known (8) to
alter the action of insulin and were measured by using high
performance liquid chromatography (sensitivity 0.1 ng/ml for
both). Additionally, factors of lipid metabolism were analyzed
in all subjects: total cholesterol and low density lipoprotein
(LDL) and high density lipoprotein (HDL) cholesterol, and
triglyceride concentration.
Statistical analysis. All results are presented as mean
value 6 SEM. Statistical analyses were performed with the
StatView 4.5 computer program (Abacus Concepts Inc.). To
overcome skewed frequency distributions, parameters were
appropriately transformed (9). When analysis of variance
showed significant differences, the Fisher post hoc test was
applied. When appropriate, Student t tests were performed. To
analyze relations between variables, simple linear regression
(least square method), multivariate analysis (assessment of
standard coefficients [SC]) and stepwise regressions (forward,
F to enter model: 4.00) were performed. A p value , 0.05 was
considered statistically significant.
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
CHF 5 chronic heart failure
HDL 5 high density lipoprotein
LDL 5 low density lipoprotein
SC 5 standard coefficient
VO2 5 oxygen consumption
528 SWAN ET AL. JACC Vol. 30, No. 2
INSULIN RESISTANCE IN CHRONIC HEART FAILURE August 1997:527–32
Results
The clinical details and results of the humoral measure-
ments are given in Table 1. Patients with CHF or coronary
artery disease and control subjects had similar age and body
mass index. The etiology of heart failure was ischemic heart
disease in 21 patients and idiopathic dilated cardiomyopathy in
17. The healthy control subjects had a significantly higher
treadmill exercise time (718 6 37 vs. 475 6 35 s) and peak VO2
(36.7 6 1.7 vs. 18.6 6 1.0 ml/kg per min, both p , 0.0001) but
a lower ventilation/carbon dioxide slope (25.1 6 0.8 vs. 36.0 6
2.5, p 5 0.005). The patients with CHF had a mean left
ventricular ejection fraction of 25.6 6 2.2%, and 6 were in New
York Heart Association class I, 8 in class II, 18 in class III and
6 in class IV. Aldosterone, plasma renin activity and norepi-
nephrine levels were increased in patients with CHF (Table 1).
The epinephrine levels of both groups were within normal
range and slightly higher in the healthy control group. Total
cholesterol and LDL cholesterol were similar in patients with
CHF and healthy control subjects, whereas HDL cholesterol
was reduced and triglyceride levels were increased in the CHF
group (Table 1).
The baseline results of insulin, glucose and C-peptide as
well the main results of the minimal model analysis of insulin
sensitivity for patients with CHF and healthy control subjects
are presented in Table 2. The patients with CHF were mark-
edly insulin resistant, with a 58% reduction in insulin sensitivity
(p , 0.0001), and they had markedly increased basal insulin
and C-peptide levels, as well as increased insulin and C-peptide
responses to the glucose load.
Analyzing all patients with CHF and healthy control sub-
jects together for the factors associated with the development
of insulin resistance, we found significant univariate correlations
between insulin sensitivity and peak VO2 (r 5 0.63) and
exercise time (r 5 0.51), fasting insulin (r 5 20.56), C-peptide
(r 5 20.53) and triglyceride levels (r 5 20.62, all p , 0.0001),
age (r 5 20.46, p , 0.0005), HDL cholesterol (r 5 0.42) and
total cholesterol (r 5 20.39, both p , 0.005), LDL cholesterol
(r 5 20.29) and body mass index (r 5 20.31, both p , 0.05)
Table 1. Clinical Details and Humoral Determinations in 38 Patients With Chronic Heart Failure and







Age (yr) 56 6 1.5 53 6 2.6 0.23
Height (cm) 174 6 0.9 177 6 1.3 0.06
Weight (kg) 82.9 6 2.0 82.6 6 2.5 0.91
Body mass index (kg/m2) 27.4 6 0.6 26.4 6 0.9 0.35
Aldosterone (pmol/liter) 770 6 134 284 6 37 0.012
Plasma renin activity (ng/ml per h) 7.70 6 1.19 1.36 6 0.16 0.0002
Norepinephrine (nmol/liter) 2.50 6 0.24 1.77 6 0.16 0.039
Epinephrine (nmol/liter) 0.39 6 0.02 0.50 6 0.04 0.012
Total cholesterol (mmol/liter)* 5.41 (10.19, 20.18) 4.91 (10.20, 20.19) 0.08
HDL cholesterol (mmol/liter)* 1.05 (10.05, 20.05) 1.24 (10.06, 20.06) 0.028
LDL cholesterol (mmol/liter)* 3.32 (10.15, 20.14) 3.11 (10.19, 20.18) 0.39
Triglyceride (mmol/liter)* 1.84 (10.19, 20.17) 1.00 (10.11, 20.10) 0.0003
*Logarithmic transformation results in asymmetric standard errors. Data are presented as mean value 6 SEM. p values
in italics indicate significant differences between groups. HDL 5 high density lipoprotein; LDL 5 low density lipoprotein.
Table 2. Insulin and Glucose Metabolism Data Assessed in 38 Patients With Chronic Heart Failure
and 20 Healthy Control Subjects






Fasting insulin (pmol/liter)† 67 (110, 29) 29 (16, 25) 0.0011
Fasting glucose (mmol/liter) 5.47 6 0.13 5.14 6 0.08 0.09
Fasting C-peptide (pmol/liter)† 746 (159, 255) 426 (142, 238) , 0.0001
Incremental insulin area
(minzpmol/liter 3 1024)†
3.00 (10.26, 20.24) 2.10 (10.22, 20.20) 0.0092
Incremental C-peptide area
(minzmmol/liter)‡
119 (111, 210) 77 (112, 211) 0.011
Insulin sensitivity
(min21/pmol/ml 3 105)‡
2.01 (10.33, 20.31) 4.84 (10.68, 20.63) , 0.0001
SG (min
21 3 102)† 1.52 (10.14, 20.12) 1.45 (10.21, 20.18) 0.75
*p values in italics indicate significant differences between groups. †Logarithmic and ‡square root transformation
results in asymmetric standard errors. Data are presented as mean values 6 SEM. SG 5 glucose-dependent glucose
elimination.
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(Fig. 1). Neither epinephrine nor norepinephrine correlated
with insulin sensitivity, fasting insulin levels or the insulin and
C-peptide response to the glucose bolus in the combined group
of patients with CHF and healthy subjects or both groups
separately. The left ventricular ejection fraction or the furo-
semide equivalent dose did also not correlate with insulin
sensitivity in the patients with CHF.
In a multivariate analysis with seven relevant factors (age,
peak VO2, exercise time, body mass index and fasting triglyc-
eride, insulin and C-peptide levels) in the patients with CHF
and healthy control subjects (n 5 58), age, peak VO2 and
triglyceride concentration were significantly and independently
correlated with insulin sensitivity (all p , 0.05). Stepwise
regression with 15 clinical and humoral factors showed in these
subjects that one after another peak VO2, fasting triglycer-
ides, age and plasma aldosterone contributed significantly to
the variation of insulin sensitivity in the 58 study subjects
(the variation of all four factors together explained 61.8% of
the variation of insulin sensitivity, p , 0.0001).
Influence of coronary artery disease. Patients with coro-
nary artery disease without CHF were less insulin sensitive
than healthy control subjects (232%, p 5 0.042), but their
insulin sensitivity was 113% higher than that of patients with
CHF due to ischemic heart disease (p 5 0.0023) (Fig. 2). The
patients with CHF due to ischemic heart disease had the
highest triglyceride and fasting insulin levels (Table 3). Pa-
tients with CHF due to dilated cardiomyopathy and the
patients with coronary artery disease without CHF had similar
glucose, insulin, triglyceride and cholesterol levels and similar
insulin sensitivity and incremental insulin area (Table 3).
A multivariate analysis of the predictors of insulin sensitiv-
ity with age, fasting insulin, triglycerides, presence of CHF and
presence of coronary artery disease in all 79 subjects showed
that the presence of coronary artery disease did not predict
impaired insulin sensitivity. Indeed, in any model that con-
tained fasting insulin or triglyceride levels, the presence of
coronary artery disease (with or without heart failure) was not
a significant independent predictor of impaired insulin sensi-
tivity (p . 0.20). Age (SC 5 20.28, p 5 0.0006), triglycerides
(SC 5 20.32, p 5 0.0023), fasting insulin (SC 5 20.29, p 5
0.0037) and presence of CHF (SC 5 20.20, p 5 0.018)
predicted impaired insulin sensitivity independently of each
other (adjusted joint R2 5 0.53, p , 0.0001).
Discussion
This study demonstrates that CHF is associated with
marked insulin resistance, and is characterized by both fasting
and stimulated hyperinsulinemia. The data expand the results
of our pilot study (3) considerably, as we studied a larger
patient group with a wider range of disease severity and
different etiology and included a second control group with
patients with coronary artery disease. A high degree of insulin
resistance was seen in patients with CHF with a 58% reduction
in insulin sensitivity and a 131% increase in fasting insulin
concentration compared with values in a healthy control group.
Figure 1. Relation between insulin
sensitivity and four clinical factors
(peak VO2, patient age [in years],
triglyceride level and epinephrine
[noradrenaline]) in 38 patients with
CHF (solid circles) and 20 healthy
control subjects (open circles). The
y axis shows insulin sensitivity
(min21/pmol/ml 3 105, square root
transformation).
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Increased severity of CHF in terms of peak VO2 (i.e., functional
exercise capacity) was significantly related to increased insulin
resistance. CHF is related to the presence of insulin resistance
independently of the presence of coronary artery disease.
Although many investigators have assumed that variations
in plasma catecholamine levels as a measure of sympathetic
activation could cause and hence correlate with insulin resis-
tance in heart failure, we could not demonstrate this hypoth-
esis in our patients. A previous study (10) demonstrated a
strong negative correlation between insulin resistance and
plasma norepinephrine (r 5 20.82) in eight patients with mild
to moderate heart failure (mainly due to valvular disease). In
the present larger study, we could not confirm this negative
correlation. Our observations do not exclude a role for sym-
pathetic overactivity at some stage in the establishment of
insulin resistance but indicate that it is unlikely to be the sole
cause. The interrelation between insulin and catecholamines is
complex. In normal subjects infusion of insulin increases
sympathetic activity (11), but infusions of either epinephrine or
norepinephrine reduce insulin levels (12,13), suggesting a
possible negative feedback mechanism. However, some studies
(14,15) have implicated increased catecholamine levels as a
cause of insulin resistance (and hyperinsulinemia) in patients
without heart disease, indicating that a disturbance of the normal
feedback mechanism may occur in insulin-resistant states.
The diagnosis of ischemic heart disease or dilated cardio-
myopathy was not associated with the abnormalities in insulin
metabolism in our study, suggesting that the insulin resistance
in CHF is not dependent on the presence of arteriosclerotic
disease of the coronary arteries. We found that patients with
ischemic heart disease and normal left ventricular function
were insulin resistant and hyperinsulinemic but to a signifi-
cantly lesser degree than patients with CHF due to ischemic
heart disease. This finding supports the suggestion that the
abnormalities of insulin metabolism occur secondary to the
heart failure itself, possibly resulting from circulatory changes
or as part of the overall neurohormonal response to heart
failure. In this context it is interesting that patients with CHF
due to dilated cardiomyopathy and patients with coronary
Figure 2. Insulin sensitivity in patients with CHF (due to ischemic
heart disease [IHD], n 5 21; dilated cardiomyopathy [DCM], n 5 17),
coronary artery disease (CAD, n 5 21) and healthy control subjects
(n 5 20). Box plot displaying the 10th, 25th, 50th, 75th and 90th
percentiles. p values for mean square root transformed insulin sensi-
tivity were obtained by Fisher post hoc test.
Table 3. Clinical Details and Measures of Carbohydrate Metabolism in Men With Chronic Heart
Failure Due to Coronary Artery Disease or Dilated Cardiomyopathy and in Men With Coronary
Artery Disease Without Chronic Heart Failure
CAD Without CHF
(n 5 21)
CHF Due to Dilated
Cardiomyopathy
(n 5 17)
CHF Due to CAD
(n 5 21)
Age (yr) 55 6 1.0 54 6 2.7 58 6 1.5
Body mass index (kg/m2) 26.0 6 0.3 27.1 6 1.0 27.7 6 0.7
Triglycerides (mmol/liter)\ 1.59 (10.15, 20.11)* 1.46 (10.24, 20.21)** 2.22 (10.27, 20.24)***†§
Total cholesterol
(mmol/liter)\
5.45 (10.22, 20.21) 5.23 (10.36, 20.34) 5.55 (10.17, 20.17)
Fasting insulin (pmol/liter)\ 56 (19, 28)** 48 (114, 211) 87 (111, 210)***§
Fasting glucose (mmol/liter) 5.39 6 0.12 5.28 6 0.10 5.63 6 0.22
Insulin sensitivity
(min21/pmol/ml 3 105)¶
3.30 (10.41, 20.38)** 2.70 (10.55, 20.50)* 1.55 (10.33, 20.30)***††§
Incremental insulin area
(minzpmol/liter 3 1024)\
2.69 (10.42, 20.37) 2.48 (10.36, 20.32) 3.48 (10.32, 20.29)*
SG (min
21 3 102)\ 1.33 (10.12, 20.11) 1.63 (10.24, 20.21) 1.45 (10.17, 20.15)
*p , 0.05, **p , 0.01 and ***p , 0.0001 versus healthy control subjects. †p , 0.05 and ††p , 0.01 versus patients
with coronary artery disease (CAD) without chronic heart failure (CHF). §p , 0.05 versus patients with chronic heart
failure due to dilated cardiomyopathy. \Logarithmic and ¶square root transformation results in asymmetric standard
errors. For mean values of healthy control subjects, see Tables 1 and 2. Data are presented as mean value 6 SEM.
SG 5 glucose-dependent glucose elimination.
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artery disease without CHF were very similarly metabolically
impaired compared to healthy control subjects.
In addition to its effects on catecholamine levels, insulin has
a marked antinatriuretic effect (16). Insulin resistance could in
the long term also therefore be detrimental to the clinical
condition of patients with CHF. This might be reflected by the
significant relation between aldosterone and insulin sensitivity
after adjusting for the effects of peak VO2, age and triglycer-
ides. Like increased sympathetic activation, reduced peripheral
blood flow has previously been demonstrated (17) to be related
to insulin resistance in humans without heart disease. The
reduction of skeletal muscle blood flow in heart failure at rest
is small and could not alone account for the degree of insulin
resistance seen in our study. Resistance to the action of insulin
at the myocardial level may reduce the availability of glucose as
an energy source for the heart muscle cells. It is possible that
this effect plays an important role in patients with CHF, but
this hypothesis could not be confirmed by significant relation
between left ventricular ejection fraction and measures of
insulin resistance.
An important finding of our study was the relation between
insulin sensitivity and severity of CHF assessed by measure-
ment of functional exercise capacity, that is, peak VO2. Peak
VO2 derived from a maximal exercise test is an index of overall
integrated cardiopulmonary function and is highly correlated
with the prognosis of heart failure (18). In contrast, left
ventricular ejection fraction is a measure of ventricular size
and the degree of myocardial damage, characteristic of the
primary event responsible for the development of CHF. In
recent studies including neurohormonal evaluation of patients
with CHF, left ventricular ejection fraction was not an inde-
pendent predictor of prognosis (19,20). Assessment of the
severity of heart failure from these two different angles and
demonstration that the measures of glucose and insulin me-
tabolism were highly correlated with peak VO2 suggests also
that insulin resistance is a consequence of heart failure rather
than a direct result of myocardial dysfunction. One could
speculate that 1) the development of insulin resistance may
also be associated with a worse prognosis and that 2) in severe
CHF and cardiac cachexia, which are characterized by muscle
atrophy and neurohormonal abnormalities (21,22), insulin
resistance (with reduced availability of glucose as an energy
source for the skeletal muscle cells) may be important in
reducing skeletal muscle strength and increasing fatigability in
these patients (21).
Although the majority of patients were taking furosemide,
it is unlikely that this agent affected their insulin sensitivity
because we found no relation between the furosemide-
equivalent dose and insulin sensitivity. The cause of insulin
resistance in heart failure remains unknown and was not
directly addressed by this study. Therefore it remains uncertain
whether insulin resistance is a primary or secondary phenom-
enon in heart failure, but our observations strongly support the
idea that insulin resistance progresses within the natural course
of heart failure and that the development of CHF has an
independent additive effect even in the presence of preexisting
coronary artery disease. The study was restricted to men;
however, it seems unlikely that observations in women with
CHF would differ substantially.
We acknowledge the assistance and support of Professor Michael Oliver.
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